SEARCH

SEARCH BY CITATION

References

  • 1
    Munoz N,Bosch FX,de Sanjose S,Herrero R,Castellsague X,Shah KV,Snijders PJ,Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 2
    Walboomers JM,Jacobs MV,Manos MM,Bosch FX,Kummer JA,Shah KV,Snijders PJ,Peto J,Meijer CJ,Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 3
    Bosch FX,Manos MM,Munoz N,Sherman M,Jansen AM,Peto J,Schiffman MH,Moreno V,Kurman R,Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796802.
  • 4
    Herrero R,Castellsague X,Pawlita M,Lissowska J,Kee F,Balaram P,Rajkumar T,Sridhar H,Rose B,Pintos J,Fernandez L,Idris A, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 177283.
  • 5
    Koutsky L Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 38.
  • 6
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 10: 10.
  • 7
    Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 191527.
  • 8
    Harper DM,Franco EL,Wheeler CM,Moscicki AB,Romanowski B,Roteli-Martins CM,Jenkins D,Schuind A,Costa Clemens SA,Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 124755.
  • 9
    Schwarz TF,Dubin G, HPV Vaccine Study Investigators for Adult Women. Human papillomavirus (HPV) 16/18 l1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years. ASCO Meet Abstr 2007; 25(18 Suppl): Abstract 3007.
  • 10
    Paavonen J,Jenkins D,Bosch FX,Naud P,Salmeron J,Wheeler CM,Chow SN,Apter DL,Kitchener HC,Castellsague X,de Carvalho NS,Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 216170.
  • 11
    Hildesheim A,Herrero R,Wacholder S,Rodriguez AC,Solomon D,Bratti MC,Schiller JT,Gonzalez P,Dubin G,Porras C,Jimenez SE,Lowy DR, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 74353.
  • 12
    Kanodia S,Fahey LM,Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007; 7: 7989.
  • 13
    Brinkman JA,Hughes SH,Stone P,Caffrey AS,Muderspach LI,Roman LD,Weber JS,Kast WM. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007; 23: 33752.
  • 14
    Roman LD,Wilczynski S,Muderspach LI,Burnett AF,Rodriguez AO,Brinkman JA,Kast WM,Facio G,Felix JC,Aldana M,Weber JS. A phase II study of Hsp-E7 (SGN-00101) in women with high grade cervical dysplasia. Gynecol Oncol 2007; 106: 55866.
  • 15
    Einstein MH,Kadish AS,Burk RD,Kim MY,Wadler S,Streicher H,Goldberg GL,Runowicz CD. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106: 45360.
  • 16
    Palefsky JM,Berry JM,Jay N,Krogstad M,Da Costa M,Darragh TM,Lee JY. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006; 20: 115155.
  • 17
    Derkay CS,Smith RJ,McClay J,van Burik JA,Wiatrak BJ,Arnold J,Berger B,Neefe JR. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 2005; 114: 73037.
  • 18
    Kaufmann AM,Nieland JD,Jochmus I,Baur S,Friese K,Gabelsberger J,Gieseking F,Gissmann L,Glasschroder B,Grubert T,Hillemanns P,Hopfl R, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer, in press.
  • 19
    Vandepapeliere P,Barrasso R,Meijer CJ,Walboomers JM,Wettendorff M,Stanberry LR,Lacey CJ. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005; 192: 2099107.
  • 20
    MAGE-A3/HPV16 peptide based immunotherapeutic vaccines for squamous cell carcinoma of the head and neck (Identifier NCT00257738), 2007.Available at www.clinicaltrials.gov.
  • 21
    Garcia-Hernandez E,Gonzalez-Sanchez JL,Andrade-Manzano A,Contreras ML,Padilla S,Guzman CC,Jimenez R,Reyes L,Morosoli G,Verde ML,Rosales R. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13: 59297.
  • 22
    Albarran YC,de la GA,Cruz Quiroz BJ,Vazquez ZE,Diaz E,I,Mendez FE,Lopez CM,Andrade-Manzano A,Padilla S,Varela AR,Rosales R. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. Bio Drugs 2007; 21: 4759.
  • 23
    A phase II trial in patients with early cervical cancer to study the safety and the immunological effects of vaccination with TA-HPV, a live recombinant vaccinia virus expressing the human papillomavirus 16 and 18 E6 and E7 proteins (Identifier NCT00002916), 2007. Available at www.clinicaltrials.gov.
  • 24
    A Multi-center, double-blind, randomized, placebo-controlled study of Amolimogene (ZYC101a) in the treatment of high-grade cervical intraepithelial lesions (CIN 2/3) of the uterine cervix (Identifier NCT00264732), 2007. Available at www.clinicaltrials.gov.
  • 25
    Fiander AN,Tristram AJ,Davidson EJ,Tomlinson AE,Man S,Baldwin PJ,Sterling JC,Kitchener HC. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006; 16: 107581.
  • 26
    Immunotherapy of recurrent cervical cancers using dendritic cells (Identifier NCT00155766), 2007. Available at www.clinicaltrials.gov.
  • 27
    Achtar MS,Ibrahim R,Herrin E,Gause B,Steinberg S,Grollman F,Rahma O,Bernstein S,Maruffi C,Berzofsky JA,Khleif SN. Pre-immature dendritic cells pulsed with Human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer. J Clin Oncol 2005; 23[16S Part I of II June 1 Supplement ( )]: 2522.
  • 28
    Active immunization of patients with carcinoma of oral cavity or oropharynx with autologous dendritic cells transfected with DNA from autologous tumor (Identifier NCT00377247), 2007. Available at www.clinicaltrials.gov.
  • 29
    Van Poelgeest MI,van Seters M,van Beurden M,Kwappenberg KM,Heijmans-Antonissen C,Drijfhout JW,Melief CJ,Kenter GG,Helmerhorst TJ,Offringa R,van der Burg SH. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005; 11: 527380.
  • 30
    Le T,Menard C,Hicks-Boucher W,Hopkins L,Weberpals J,Fung-Kee-Fung M. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol 2007; 106: 57984.
  • 31
    Wieland U,Brockmeyer NH,Weissenborn SJ,Hochdorfer B,Stucker M,Swoboda J,Altmeyer P,Pfister H,Kreuter A. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006; 142: 143844.
  • 32
    A randomized, double-blind, three-arm parallel-group, placebo controlled phase 3 trial to investigate the clinical efficacy and safety of Polyphenon E in the treatment of external genital warts (Identifier NCT00449982), 2007. Available at www.clinicaltrials.gov.
  • 33
    Schofer H,Van Ophoven A,Henke U,Lenz T,Eul A. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006; 16: 64248.
  • 34
    A limited access phase II trial of cetuximab (C225, NSC #714692) in combination with cisplatin (NSC#119875) in the treatment of advanced, persistent, or recurrent carcinoma of the cervix (Identifier NCT00101192), 2007. Available at www.clinicaltrials.gov.
  • 35
    A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma (Identifier NCT00369122), 2007. Available at www.clinicaltrials.gov.
  • 36
    A phase I trial of tailored radiation therapy with concomitant cetuximab (C225, NSC #714692) and cisplatin (NSC #119875) in the treatment of patients with cervical cancer (Identifier NCT00104910), 2007. Available at www.clinicaltrials.gov.
  • 37
    Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 57177.
  • 38
    Stary G,Bangert C,Tauber M,Strohal R,Kopp T,Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 144151.
  • 39
    Wolf IH,Kodama K,Cerroni L,Kerl H. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol 2007; 29: 23741.
  • 40
    Schon M,Bong AB,Drewniok C,Herz J,Geilen CC,Reifenberger J,Benninghoff B,Slade HB,Gollnick H,Schon MP. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 113849.
  • 41
    Molling JW,de Gruijl TD,Glim J,Moreno M,Rozendaal L,Meijer CJ,van den Eertwegh AJ,Scheper RJ,von Blomberg ME,Bontkes HJ. CD4(+)CD25(hi) regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007; 121: 174955.
  • 42
    Piersma SJ,Jordanova ES,Van Poelgeest MI,Kwappenberg KM,van der Hulst JM,Drijfhout JW,Melief CJ,Kenter GG,Fleuren GJ,Offringa R,van der Burg SH. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67: 35461.
  • 43
    Nakagawa M,Stites DP,Farhat S,Judd A,Moscicki AB,Canchola AJ,Hilton JF,Palefsky JM. T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol 1996; 3: 20510.
  • 44
    de Jong A,van der Burg SH,Kwappenberg KM,van der Hulst JM,Franken KL,Geluk A,van Meijgaarden KE,Drijfhout JW,Kenter G,Vermeij P,Melief CJ,Offringa R. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 47279.
  • 45
    Welters MJ,de Jong A,van den Eeden SJ,van der Hulst JM,Kwappenberg KM,Hassane S,Franken KL,Drijfhout JW,Fleuren GJ,Kenter G,Melief CJ,Offringa R, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63: 63641.
  • 46
    de Jong A,Van Poelgeest MI,van der Hulst JM,Drijfhout JW,Fleuren GJ,Melief CJ,Kenter G,Offringa R,van der Burg SH. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 544955.
  • 47
    Bontkes HJ,de Gruijl TD,van den Muysenberg AJ,Verheijen RH,Stukart MJ,Meijer CJ,Scheper RJ,Stacey SN,Duggan-Keen MF,Stern PL,Man S,Borysiewicz LK, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000; 88: 928.
  • 48
    Welters MJ,van der LP,van den Eeden SJ,Kwappenberg KM,Drijfhout JW,Fleuren GJ,Kenter GG,Melief CJ,van der Burg SH,Offringa R. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006; 118: 9506.
  • 49
    Nakagawa M,Stites DP,Farhat S,Sisler JR,Moss B,Kong F,Moscicki AB,Palefsky JM. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997; 175: 92731.
  • 50
    Nakagawa M,Viscidi R,Deshmukh I,Costa MD,Palefsky JM,Farhat S,Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol 2002; 9: 87782.
  • 51
    Valdespino V,Gorodezky C,Ortiz V,Kaufmann AM,Roman-Basaure E,Vazquez A,Berumen J. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol Oncol 2005; 96: 92102.
  • 52
    Ressing ME,van Driel WJ,Celis E,Sette A,Brandt MP,Hartman M,Anholts JD,Schreuder GM,ter Harmsel WB,Fleuren GJ,Trimbos BJ,Kast WM, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996; 56: 5828.
  • 53
    Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002; 89: 24961.
  • 54
    Feltkamp MC,Smits HL,Vierboom MP,Minnaar RP,de Jongh BM,Drijfhout JW,ter Schegget J,Melief CJ,Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 22429.
  • 55
    Feltkamp MC,Vreugdenhil GR,Vierboom MP,Ras E,van der Burg SH,ter Schegget J,Melief CJ,Kast WM. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995; 25: 263842.
  • 56
    van Hall T,van de Rhee NE,Schoenberger SP,Vierboom MP,Verreck FA,Melief CJ,Offringa R. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res 1998; 58: 308793.
  • 57
    Lin KY,Guarnieri FG,Staveley-O'Carroll KF,Levitsky HI,August JT,Pardoll DM,Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 216.
  • 58
    Engelhard VH,Lacy E,Ridge JP. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J Immunol 1991; 146: 122632.
  • 59
    Shirai M,Arichi T,Nishioka M,Nomura T,Ikeda K,Kawanishi K,Engelhard VH,Feinstone SM,Berzofsky JA. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995; 154: 273342.
  • 60
    Peng S,Trimble C,He L,Tsai YC,Lin CT,Boyd DA,Pardoll D,Hung CF,Wu TC. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther 2006; 13: 6777.
  • 61
    Eiben GL,Velders MP,Schreiber H,Cassetti MC,Pullen JK,Smith LR,Kast WM. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002; 62: 57929.
  • 62
    Melero I,Singhal MC,McGowan P,Haugen HS,Blake J,Hellstrom KE,Yang G,Clegg CH,Chen L. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J Virol 1997; 71: 39984004.
  • 63
    Souders NC,Sewell DA,Pan ZK,Hussain SF,Rodriguez A,Wallecha A,Paterson Y. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun 2007; 7: 2.
  • 64
    Hu J,Peng X,Schell TD,Budgeon LR,Cladel NM,Christensen ND. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol 2006; 177: 803745.
  • 65
    Wood CE,Borgerink H,Register TC,Scott L,Cline JM. Cervical and vaginal epithelial neoplasms in cynomolgus monkeys. Vet Pathol 2004; 41: 10815.
  • 66
    Wood CE,Chen Z,Cline JM,Miller BE,Burk RD. Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. J Virol 2007; 81: 633945.
  • 67
    Blanchet JS,Valmori D,Dufau I,Ayyoub M,Nguyen C,Guillaume P,Monsarrat B,Cerottini JC,Romero P,Gairin JE. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J Immunol 2001; 167: 585261.
  • 68
    Chen YF,Lin CW,Tsao YP,Chen SL. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004; 78: 133343.
  • 69
    Torrens I,Mendoza O,Batte A,Reyes O,Fernandez LE,Mesa C,Guillen G. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 2005; 23: 576874.
  • 70
    Daftarian P,Mansour M,Benoit AC,Pohajdak B,Hoskin DW,Brown RG,Kast WM. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006; 24: 523544.
  • 71
    Daftarian PM,Mansour M,Pohajdak B,Fuentes-Ortega A,Korets-Smith E,Macdonald L,Weir G,Brown RG,Kast WM. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax(R) encapsulated CTL/T helper peptides. J Transl Med 2007; 5: 26.
  • 72
    Vambutas A,DeVoti J,Nouri M,Drijfhout JW,Lipford GB,Bonagura VR,van der Burg SH,Melief CJ. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005; 23: 527180.
  • 73
    Rosenberg SA,Yang JC,Sherry RM,Hwu P,Topalian SL,Schwartzentruber DJ,Restifo NP,Haworth LR,Seipp CA,Freezer LJ,Morton KE,Mavroukakis SA, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003; 14: 70914.
  • 74
    Miller AM,Ozenci V,Kiessling R,Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother (1997) 2005; 28: 38995.
  • 75
    Li Y,Subjeck J,Yang G,Repasky E,Wang XY. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006; 24: 536070.
  • 76
    Lu Y,Zhang Z,Liu Q,Liu B,Song X,Wang M,Zhao X,Zhao Q. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Biol Pharm Bull 2007; 30: 1506.
  • 77
    Ohlschlager P,Pes M,Osen W,Durst M,Schneider A,Gissmann L,Kaufmann AM. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006; 24: 288093.
  • 78
    Brinkman JA,Xu X,Kast WM. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 2007; 25: 343744.
  • 79
    Bermudez-Humaran LG,Cortes-Perez NG,Lefevre F,Guimaraes V,Rabot S,Alcocer-Gonzalez JM,Gratadoux JJ,Rodriguez-Padilla C,Tamez-Guerra RS,Corthier G,Gruss A,Langella P. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175: 7297302.
  • 80
    Coukos G,Conejo-Garcia JR,Roden RB,Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 2005; 5: 1193210.
  • 81
    Bungener L,de Mare A,de Vries-Idema J,Sehr P,van der Zee A,Wilschut J,Daemen T. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther 2006; 11: 71727.
  • 82
    Gomez-Gutierrez JG,Elpek KG,Montes de Oca-Luna R,Shirwan H,Sam Zhou H,McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007; 56: 9971007.
  • 83
    Qian J,Dong Y,Pang YY,Ibrahim R,Berzofsky JA,Schiller JT,Khleif SN. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006; 118: 30229.
  • 84
    Dallo S,Maa JS,Rodriguez JR,Rodriguez D,Esteban M. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 1989; 173: 3239.
  • 85
    Daemen T,Riezebos-Brilman A,Regts J,Dontje B,van der Zee A,Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004; 9: 73342.
  • 86
    Riezebos-Brilman A,Regts J,Freyschmidt EJ,Dontje B,Wilschut J,Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 2005; 12: 141014.
  • 87
    Nishimoto KP,Laust AK,Wang K,Kamrud KI,Hubby B,Smith JF,Nelson EL. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol 2007; 20: 88104.
  • 88
    Cassetti MC,McElhiney SP,Shahabi V,Pullen JK,Le Poole IC,Eiben GL,Smith LR,Kast WM. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004; 22: 5207.
  • 89
    Fausch SC,Da Silva DM,Rudolf MP,Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169: 32429.
  • 90
    Fausch SC,Da Silva DM,Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003; 63: 347882.
  • 91
    Lenz P,Thompson CD,Day PM,Bacot SM,Lowy DR,Schiller JT. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 2003; 106: 2317.
  • 92
    Fausch SC,Fahey LM,Da Silva DM,Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol 2005; 174: 71728.
  • 93
    Ward S,Sotsios Y,Dowden J,Bruce I,Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003; 10: 20713.
  • 94
    Workman P Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004; 32 (Part 2): 3936.
  • 95
    Ward SG,Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003; 3: 42634.
  • 96
    Yaguchi S,Fukui Y,Koshimizu I,Yoshimi H,Matsuno T,Gouda H,Hirono S,Yamazaki K,Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 54556.
  • 97
    Zarember KA,Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 55461.
  • 98
    Renn CN,Sanchez DJ,Ochoa MT,Legaspi AJ,Oh CK,Liu PT,Krutzik SR,Sieling PA,Cheng G,Modlin RL. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol 2006; 177: 298305.
  • 99
    Flacher V,Bouschbacher M,Verronese E,Massacrier C,Sisirak V,Berthier-Vergnes O,de Saint-Vis B,Caux C,Dezutter-Dambuyant C,Lebecque S,Valladeau J. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006; 177: 795967.
  • 100
    Ito T,Amakawa R,Kaisho T,Hemmi H,Tajima K,Uehira K,Ozaki Y,Tomizawa H,Akira S,Fukuhara S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 150712.
  • 101
    Gorden KB,Gorski KS,Gibson SJ,Kedl RM,Kieper WC,Qiu X,Tomai MA,Alkan SS,Vasilakos JP. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 125968.
  • 102
    Yang R,Murillo FM,Delannoy MJ,Blosser RL,Yutzy WHt,Uematsu S,Takeda K,Akira S,Viscidi RP,Roden RB. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005; 174: 791219.
  • 103
    Yan M,Peng J,Jabbar IA,Liu X,Filgueira L,Frazer IH,Thomas R. Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol Cell Biol 2005; 83: 8391.
    Direct Link:
  • 104
    Hasan UA,Bates E,Takeshita F,Biliato A,Accardi R,Bouvard V,Mansour M,Vincent I,Gissmann L,Iftner T,Sideri M,Stubenrauch F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 318697.
  • 105
    Dolmans DE,Fukumura D,Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 3807.
  • 106
    Abdel-Hady ES,Martin-Hirsch P,Duggan-Keen M,Stern PL,Moore JV,Corbitt G,Kitchener HC,Hampson IN. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001; 61: 1926.
  • 107
    Ichimura H,Yamaguchi S,Kojima A,Tanaka T,Niiya K,Takemori M,Hasegawa K,Nishimura R. Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial neoplasia. Int J Clin Oncol 2003; 8: 3225.
  • 108
    Bae SM,Kim YW,Kwak SY,Ro DY,Shin JC,Park CH,Han SJ,Oh CH,Kim CK,Ahn WS. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells. Cancer Sci 2007; 98: 74752.
  • 109
    Scholten KB,Schreurs MW,Ruizendaal JJ,Kueter EW,Kramer D,Veenbergen S,Meijer CJ,Hooijberg E. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 2005; 114: 11929.
  • 110
    Lyons GE,Roszkowski JJ,Man S,Yee C,Kast WM,Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 2006; 55: 114250.